drugset / Trial / NCT04465357
Efficacy of Erenumab on Functional Impact of Migraine
Phase 4
Completed
55 enrolled
Merle Diamond
Clinvest Research, LLC · collabSmith, Timothy R., M.D. · collab
NaSingle-groupOpen-labelSupportive care
Summary
The purpose of this study is to assess the efficacy of erenumab on functional impact due to Migraine in adults.
Timeline
- Start
- 2020-10-22
- Primary completion
- 2022-06-03
- Completion
- 2022-06-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erenumab | Monoclonal antibody | 140 mg/ml | Subcutaneous |